Vitrafy Life Sciences (VFY) investor relations material

Executive summary

• Delivered the first production unit of the VCU2 cryopreservation device, a major IPO milestone, enabling immediate market entry and scalability.

• Expanded U.S. operations with key hires in sales, marketing, and commercial roles to support North American market entry and commercialization.

• Initiated board and executive renewal, including CEO transition and appointment of Dr. Lee Farrell as incoming Chair, to strengthen expertise and support growth.

• Achieved commercialisation milestones in aquaculture and blood platelets with strategic partners, including Huon Aquaculture and the U.S. Army Institute of Surgical Research.

• Maintained a strong financial position with cash expenditure tracking in line with expectations.

Financial highlights

• Ended Q1 FY2026 with AUD 25.8 million in cash and term deposits, providing a runway into 2027.

• Q1 net cash burn was AUD 3.7 million, with cash costs at AUD 4.2 million, down from AUD 4.7 million in the prior period.

• Receipts from customers totaled $52,000; interest received was $429,000.

• Expecting AUD 2.4 million in grant funding over the next 12 months.

• Estimated 7 quarters of funding available, including term deposits.

Outlook and guidance

• Preparing for scaled manufacturing and deployment of VCU2 devices, with three additional units in production and plans to outsource manufacturing, including U.S. partnerships.

• Anticipating FDA medical device registration by mid-2026, enabling further market expansion.

• Focused on converting a strong pipeline into commercial agreements and scaling up production, with further updates expected at the AGM in November 2025.